Not logged in Share Save
Share Save
Share Save
Nivolumab for Resected Stage III or IV Melanoma at 9 Years Ascierto, Paolo A.; Del Vecchio, Michele; Merelli, Barbara; Gogas, Helen; Arance, Ana M.; Dalle, Stephane; Cowey, Charles Lance; Schenker, Michael; Gaudy-Marqueste, Caroline; Pigozzo, Jacopo; Marquez-Rodas, Ivan; Butler, Marcus O.; Di Giacomo, Anna Maria; Gligich, Oleg; de la Cruz-merino, Luis; Arenberger, Petr; Atkinson, Victoria; Nathan, Paul; Hill, Andrew; Millward, Michael; Fecher, Leslie A.; Khushalani, Nikhil I.; Queirolo, Paola; Soomro, Raheela; Rathod, Dhanrajsinh; Askelson, Margarita; Pe Benito, Melanie; Joseph, Devanand; Larkin, James Share Save
A signal-seeking phase 2 study of Trastuzumab emtansine in tumours harbouring HER2 amplification or mutation Thavaneswaran, Subotheni; Lin, Frank; Grady, John P.; Espinoza, David; Huang, Min Li; Chinchen, Sarah; Sebastian, Lucille; Kansara, Maya; Mersiades, Tony; Lee, Chee Khoon; Desai, Jayesh; Grimison, Peter; Brown, Michael; Millward, Michael; Harrup, Rosemary; O'Byrne, Ken; Nagrial, Adnan; Craft, Paul; Simes, John; Joshua, Anthony M.; Thomas, David M. Share Save
Phase II trial of vemurafenib (VEM) and cobimetinib (COB) in BRAF V600-mutated solid tumours and first-line (1L) non-small cell lung cancer (NSCLC): Australian molecular screening and therapeutics (MoST) substudy 12 Lin, F. P.; Mersiades, A.; Lee, J.; Xu, W.; Chinchen, S.; Charakidis, M.; Thavaneswaran, S.; Hughes, B. G. M.; Underhill, C. R.; Takhar, H. S.; Harrup, R.; Nagrial, A.; Millward, M.; Desai, J.; Espinoza, D.; Lee, C. K.; Solomon, B. J.; Simes, J.; Pavlakis, N.; Thomas, D. Share Save
Results from the first-in-human study of ATR inhibitor, IMP9064 monotherapy dose escalation in patients with advanced solid tumors Lin, C-C.; Schneider, R.; Gutierrez, M.; Shen, L.; Chung, K.; Doroshow, D. B.; Gao, B.; Millward, M.; Hsieh, C-Y.; Xu, C.; Cai, S. X.; Tian, Y. E.; Liu, L.; Shen, C.; Tan, Y.; He, Y.; Zhang, C.; Li, L.; Ma, M.; Xu, L. Share Save
Immune checkpoint therapy responders display early clonal expansion of tumor infiltrating lymphocytes Kidman, Joel; Zemek, Rachael M.; Sidhom, John-William; Correa, Debora; Principe, Nicola; Sheikh, Fezaan; Fear, Vanessa S.; Forbes, Catherine A.; Chopra, Abha; Boon, Louis; Zaitouny, Ayham; de Jong, Emma; Holt, Robert A.; Jones, Matt; Millward, Michael J.; Lassmann, Timo; Forrest, Alistair R. R.; Nowak, Anna K.; Watson, Mark; Lake, Richard A.; Lesterhuis, W. Joost; Chee, Jonathan Share Save
Share Save
Share Save
Clinical activity of lirafugratinib (RLY-4008), a highly selective FGFR2 inhibitor, in patients with advanced FGFR2-altered solid tumors: The ReFocus study Schram, Alison M.; Subbiah, Vivek; Liao, Chih-Yi (Andy); Moreno, Victor; Desamparados, Roda; Ponz-Sarvise, Mariano; Dotan, Efrat; Cassier, Philippe Alexandre; Moreno, Irene; Varkaris, Andreas; Kim, Richard D.; Garralda, Elena; Opdam, Frans; Tai, David; Italiano, Antoine; Oh, Do-Youn; Goyal, Lipika; Fontana, Elise; Liu, Jia; Boukovala, Myrto; Ghiringelli, Francois; Borad, Mitesh J.; Babiker, Hani; Jin, Zhaohui; Millward, Michael; Yachnin, Jeffrey; Kamath, Suneel Deepak; Coward, Jermaine M.; Yoo, Changhoon; Kelley, Robin Kate; Sahai, Vaibhav; Bridgewater, John; Springfield, Christoph; Florou, Vaia; El-Khoueiry, Anthony; Eskens, Ferry; Lin, Bruce; Paulson, Scott; Curigliano, Giuseppe; Murphy, Meredith; Deary, Alicia; Ricard, Fabien; Jen, Kai Yu; Ramirez, Florence (Tianhui); Blakesley, Rick E.; Schmidt-Kittler, Oleg; Mar, Brenton G.; Park, Joon Oh; Hollebecque, Antoine Share Save
Efficacy and safety outcomes of ABN401 in NSCLC patients with MET Exon 14 Skipping: A clinically relevant subgroup analysis Lee, Se-Hoon; Han, Ji-Youn; Lee, Ki Hyeong; Lee, Gyeong-Won; Lemech, Charlotte; Millward, Michael; Roohullah, Aflah; Le, Xiuning; Park, Keunchil; Choi, Jun Young; Kim, Na Young; Im, Sunyhe; Rajasekaran, Nirmal; Park, Kyung Eui; Lee, Sangsuk; Moon, Hanlim; Hwang, Sunjin; Shin, YoungKee; Lee, Dae Ho Share Save
Share Save
A phase 1a/1b first-in-human study (COMPASSION-01) evaluating cadonilimab in patients with advanced solid tumors Frentzas, Sophia; Gan, Hui K.; Cosman, Rasha; Coward, Jermaine; Tran, Ben; Millward, Michael; Zhou, Yiting; Wang, Wenjing; Xia, Dennis; Wang, Zhongmin Maxwell; Li, Baiyong; Xia, Michelle; Desai, Jayesh Share Save
AXA-042, a systemically administered TLR2/6 agonist, demonstrates target engagement and TLR pathway activation in patients with advanced solid tumors Tran, B.; Millward, M.; Lemech, C.; Frentzas, S.; Day, D.; Latifi, A.; Desai, J.; Wabnitz, P.; Kearney, P.; Galkin, A. Share Save
Share Save
Share Save
First-in-human study of ATR inhibitor IMP9064 monotherapy and in combination with PARP inhibitor senaparib in patients with advanced solid tumors Lin, C-C.; Schneider, R. E.; Gutierrez, M.; Shen, L.; Gao, B.; Chung, K.; Doroshow, D. B.; Millward, M.; Hsieh, C-Y.; Xu, C.; Cai, S. X.; Tian, Y. E.; Liu, L.; Shen, C.; Li, B.; Tan, Y.; Zhang, C.; Li, L.; Ma, M.; Chen, X. Share Save
A phase Ia/Ib, first-in-human, dose-escalation study evaluating the safety, tolerability, and efficacy of IOS-1002, a LILRB1, LILRB2, and KIR3DL1 targeting HLA-derived fusion protein administered alone or in combination with a PD-1 antibody in patients with advanced solid tumors Luen, S. J.; Ahern, E. S.; Berger, C.; Desai, J.; Frentzas, S.; Gan, H.; Gualandi, M.; Markman, B.; Millward, M.; Rafiei, A.; Tran, B.; Renner, C. Share Save
.png){kind=icon}
.png){kind=icon}
.png)
ANNALS OF ONCOLOGY.png)
OAAI
.png){kind=icon}
Share.png){kind=icon}
Save